Kangchen Pharmaceuticals: KC1036 second-line therapy for late-stage esophageal squamous cell carcinoma pivotal Phase III clinical study approved by CDE.

Kangchen Pharmaceutical announced that KC1036, a drug developed independently by the company, has been approved by the National Medical Products Administration Drug Evaluation Center to conduct pivotal Phase III clinical trials. The trials will evaluate the efficacy of KC1036 in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma who have failed first-line immunotherapy combined with chemotherapy. KC1036 is a Class 1 innovative drug developed independently by the company, with strong VEGFR vascular targeting properties that inhibit tumor cell growth. By inhibiting AXL, it can improve the host's anti-tumor immune response and prevent tumor immune escape. Currently, clinical studies on KC1036 for digestive system tumors, thymic tumors, and children with Ewing sarcoma are underway, with over 350 participants showing outstanding anti-tumor activity and safety.